Purchase this article with an account.
D. O. Rascon-Vargas, J. Fromow-Guerra, G. Cervantes-Coste, A. Perez-Montesinos, E. Torres-Porras, H. Ruíz-García, V. Morales-Canton; Effectiveness and Safety of Topical Nepafenac in Macular Edema Related to Pan-Retinal Photocoagulation. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1351.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate effectiveness and safety of topical nepafenac 0.1 % (qid) (Nevanac, Alcon Labs), in modulating macular thickening related to pan-retinal photocoagulation in diabetic patients.
Nineteen patients were included. There was no statistically significant difference between baseline values of central macular thickness and BCVA between the two groups. Wilcoxon test showed statistically significant increase in macular thickness in both groups, baseline versus two weeks after PRP. No statistically significant differences (U Mann-Whitney test) were found when macular thickness and BCVA were compared between the two groups, two weeks after PRP. 72% of patients experimented transient blurred vision in eye asigned to nepafenac. No other adverse effect was found in both groups.
Clinical Trial: :
This PDF is available to Subscribers Only